Thanks for the news Profit Taker. Looking back it seems that...

Thanks for the news Profit Taker.

Looking back it seems that many option holders have missed out due to the longer than expected development time. I am wondering if overly ambitious goals precluded fair reward for the stakeholders. Does the granting of performance shares and options in the OIS balance this, or is it being greedy? Afterall, the people doing the development should be fairly rewarded.

From what you are saying it sounds like it is being viewed as greedy.

The news on E Coli was fantastic.

Does anyone know if one final surface treatment is effective against multiple bacteria, eg. E Coli AND P aeruginosa?

Hopefully we will hear about the animal trials for the contact lenses soon.